Clinical Trials on Gastric or Duodenal Ulcers in South Africa

Total 42 results

AstraZeneca

Completed

Study of Esomeprazole 20 mg or 40 mg vs Placebo Effectiveness on the Occurrence of Peptic Ulcers in Subjects on Low Dose Acetylsalicylic Acid (LDA) (Oberon)

Gastric Ulcer | Duodenal Ulcer

United States, Bulgaria, Czech Republic, Korea, Republic of, Russian Federation, South Africa, Philippines, Poland, Romania, Finland, Norway, Canada, Mexico, Argentina, Australia, Germany, Portugal, Slovakia, Thailand, Indonesia
AstraZeneca

Completed

A Study to Prevent Rebleeding After Initial Successful Primary Endoscopic Haemostasis of a Bleeding Peptic Ulcer

Gastrointestinal Hemorrhage

Sweden, Russian Federation, South Africa, Spain, Turkey, United Kingdom, Germany, Romania, Finland, Norway, Hong Kong, Austria, Denmark, Netherlands, Greece, France
Logical Therapeutics
PRA Health Sciences

Completed

Rates of Gastric Ulcer by Endoscopy in Knee Osteoarthritis Patients Receiving LT-NS001 Versus Naprosyn®

Osteoarthritis

United States
DiaSorin Inc.
ICON Clinical Research

Completed

Helicobacter Pylori Sample Collection Protocol Pre Therapy Subjects

Nausea | Abdominal Pain | Weight Loss | Helicobacter Pylori Infection | Gastric Ulcer | Stomach Ulcer | Loss of Appetite | Bloating

United States, Italy
Gianluca Costa

Recruiting

Laparoscopic Versus Open Repair of Peptic Ulcer Perforation (LOREPUP)

Emergencies | Surgery | Peptic Ulcer Perforation

Italy
Shanghai Miracogen Inc.

Recruiting

A Study of MRG002 in Patients With HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer

Advanced Solid Tumors | Advanced or Metastatic Gastric Cancer | Advanced or Metastatic Gastroesophageal Junction Cancer

United States
Takeda

Completed

Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis

Esophagitis, Peptic | Esophagitis, Reflux

United States, Poland, Bulgaria, India, South Africa, Canada, Peru, New Zealand, Australia, Lithuania, Slovakia, Hungary, Latvia, Germany, Czech Republic
Takeda

Completed

Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis

Esophagitis, Peptic | Esophagitis, Reflux

United States, Poland, Bulgaria, India, Canada, Peru, Russian Federation, Australia, New Zealand, Czech Republic, Slovakia, South Africa, Latvia, Lithuania, Colombia, Germany
Ironwood Pharmaceuticals, Inc.

Completed

Ph2a Study to Evaluate IW-3718 in Patients With Gastroesophageal Reflux Not Completely Responsive to Proton Pump Inhibitors

Gastroesophageal Reflux

United States
Takeda

Completed

Comparison of the Classical Healing Concept With the Complete Remission Concept After Treatment With Pantoprazole in Adult Patients With Erosive GERD (Gastroesophageal Reflux Disease) (BY1023/M3-342)

Gastroesophageal Reflux Disease

Germany, Poland, Brazil, South Africa
Takeda

Completed

Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis

Esophagitis, Peptic | Esophagitis, Reflux

United States
Takeda

Completed

Efficacy and Safety of Dexlansoprazole MR Compared to Placebo on Maintaining Healing in Subjects With Healed Erosive Esophagitis

Esophagitis, Peptic | Esophagitis, Reflux

United States, Canada, Czech Republic, Lithuania, Slovakia, Latvia, Estonia, Australia
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Open Label Safety Study of Enteric-Coated Spheroid Suspension in Infants Aged Less Than 12 Months With Presumed Gastroesophageal Reflux Disease (GERD)

Gastroesophageal Reflux

Belgium, Italy, United States, Australia, Canada, France, Germany, Netherlands, Poland, South Africa, Switzerland
Takeda

Completed

Determination of the Minimal Clinically Important Difference After Treatment With Pantoprazole in Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-340)

Gastroesophageal Reflux

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)

Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | Gastric Cancer Third Line

Spain, Italy, Australia, Korea, Republic of, Belgium, France, Poland, United States, Czechia, Germany
Takeda

Completed

Efficacy of Dexlansoprazole MR on Heartburn Control in Participants Previously Receiving Twice Daily Proton Pump Inhibitor Therapy

Gastroesophageal Reflux

United States
Torax Medical Incorporated

Completed

LINX Reflux Management System in Subjects With GERD Who Have Previously Undergone a Laparoscopic Sleeve Gastrectomy (RELIEF)

Gastroesophageal Reflux Disease | GERD

United States
Ironwood Pharmaceuticals, Inc.

Completed

A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD)

Gastroesophageal Reflux Disease

United States
Eisai Inc.

Completed

Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

Gastroesophageal Reflux Disease (GERD)

Chile, Canada, United States, Estonia, India, Hungary, Bulgaria, Croatia, Australia, Lithuania, Latvia, Argentina, France, Germany
Addex Pharma S.A.

Completed

ADX10059 as an add-on Therapy to Proton Pump Inhibitors (PPIs) in Patients With Gastroesophageal Reflux (GERD)

Gastroesophageal Reflux

United States, France, Germany, Netherlands, Switzerland
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW)

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

United States, Korea, Republic of, China, Spain, Taiwan, Japan, Argentina, Canada, Croatia, Greece, Ireland, Malaysia, Netherlands, Portugal, Romania, Thailand, Turkey, United Kingdom
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer (Spotlight)

Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma

United States, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Mexico, Peru, Poland, Spain, Taiwan, United Kingdom
Eisai Inc.

Completed

Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With Rabeprazole

Gastroesophageal Reflux Disease

United States
BeiGene

Completed

Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer

Advanced or Inoperable Gastric Cancer

United States, Hungary, Spain, China, Hong Kong, Japan, Australia, Taiwan, Belgium, Czechia, Singapore, France, Poland, United Kingdom, Romania, Russian Federation, Georgia
Takeda

Completed

Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Gastroesophageal Reflux Disease

Gastroesophageal Reflux Disease

United States
Takeda

Completed

Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Heartburn

Gastroesophageal Reflux Disease

United States
Eisai Inc.

Completed

Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)

Gastroesophageal Reflux Disease (GERD)

United States
Takeda

Completed

Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Symptomatic Non-Erosive Gastroesophageal Reflux Disease in Adolescents

Gastroesophageal Reflux Disease

United States, Poland, Belgium, Portugal, Italy, Hungary, Mexico, Brazil
Braintree Laboratories

Completed

Safety and Efficacy Study of Axid Use in Infants Suffering From Gastroesophageal Reflux Disease (GERD)

Gastroesophageal Reflux Disease | GERD | Heartburn

United States
Takeda

Completed

Effect of Pantoprazole on the Symptoms of Acid Reflux Disease in Adult Patients (BY1023/M3-341)

Gastroesophageal Reflux Disease (GERD)

United Kingdom, Australia, Belgium, Spain, Austria, Germany, Argentina, Brazil, Canada, France, Hong Kong, India, Italy, Korea, Republic of, Malaysia, Mexico, Poland, Portugal, Singapore, South Africa, Switzerland, Taiwan
Eisai Inc.

Completed

Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)

Gastroesophageal Reflux Disease (GERD)

Canada, Chile, Hungary, Bulgaria, Estonia, Latvia, United States, Croatia, Australia, India, Argentina, France, Germany
Ironwood Pharmaceuticals, Inc.

Terminated

A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)

Gastroesophageal Reflux Disease (GERD)

Canada, United States
Shire

Completed

Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)

Gastroesophageal Reflux Disease

United States, Czechia, Germany, Latvia, Poland, Romania
Ironwood Pharmaceuticals, Inc.

Completed

Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)

Gastroesophageal Reflux Disease (GERD)

United States, Canada
AstraZeneca

Completed

Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study US

Gastroesophageal Reflux Disease

United States
Eisai Inc.

Completed

Comparing the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD)

Symptomatic Gastroesophageal Reflux Disease (sGERD)

United States
Hoffmann-La Roche
BioLineRx, Ltd.; Halozyme Therapeutics

Active, not recruiting

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma

United States, United Kingdom, Australia, Korea, Republic of, Taiwan, Israel, Spain
Genentech, Inc.

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Melanoma | Cervical Cancer | HCC | Gastric Cancer | Esophageal Cancer | NSCLC | Urothelial Carcinoma | HNSCC | Locally Advanced or Metastatic Solid Tumors | TNBC | Clear Cell RCC

Korea, Republic of, Netherlands, Spain, United States, Australia, Canada, Belgium
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)

Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction

United States, Spain, Italy, Australia, Russian Federation, Taiwan, Korea, Republic of, Thailand, Canada, Turkey, Germany, Romania, United Kingdom, Hungary, Brazil, France, Japan
MedImmune LLC

Completed

A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma

Gastric or Gastroesophageal Junction Adenocarcinoma

Canada, United States, Taiwan, Korea, Republic of, Japan, Singapore
University of Nebraska

Recruiting

Integrated Cancer Repository for Cancer Research (iCaRe2)

Melanoma | Sarcoma | Kidney Cancer | Leukemia | Breast Cancer | Laryngeal Cancer | Hypopharyngeal Cancer | Nasopharyngeal Cancer | Multiple Myeloma | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Small Intestine Cancer | Ovarian Cancer | Lynch Syndrome | Lung Cancer | Rectal Cancer | Prostate Cancer | Gastrointestinal... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Malignant Solid Neoplasm | Nasopharyngeal Carcinoma | Adenoid Cystic Carcinoma | Transitional Cell Carcinoma | Cholangiocarcinoma | Intrahepatic Cholangiocarcinoma | Chordoma | Gestational Trophoblastic Tumor | Pseudomyxoma Peritonei | Cervical Adenocarcinoma | Vaginal Adenocarcinoma | Vaginal Squamous Cell... and other conditions

United States, Guam

Clinical Trials on Gastric or Duodenal Ulcers in South Africa

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Paraguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations